secwatch.observer — SEC 8-K summary
======================================

Issuer:     Carisma Therapeutics Inc. (CARM)
CIK:        0001485003
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001104659-24-087014
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Carisma Therapeutics Q2 2024 net loss $11.2M; CT-0525 data expected by year-end
-------------------------------------------------------------------------------

- Net loss improved to $11.2M in Q2 2024 from $19.9M in Q2 2023; R&D expenses declined to $15.3M.
- Cash and equivalents $40.4M at June 30, 2024; expects to fund operations into Q3 2025.
- Initial data from CT-0525 Phase 1 trial for HER2+ solid tumors expected by year-end 2024; FDA Fast Track granted.
- Nominated first in vivo CAR-M development candidate targeting GPC3 under Moderna collaboration; $2.0M milestone received.
- Liver fibrosis program development candidate nomination expected in Q1 2025; preclinical data at AASLD in Nov 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1485003/000110465924087014/0001104659-24-087014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1485003/000110465924087014/tm2420899d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-087014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer